Comparison of Culture With Antibiogram to Next-Generation Sequencing Using Bacterial Isolates and Formalin-Fixed, Paraffin-Embedded Gastric Biopsies

Overview

Journal Gastroenterology

Specialty Gastroenterology

Date 2021 Jul 22

PMID 34293298

Citations 23

Authors

Kristina G Hulten

Robert M Genta

Ira N Kalfus

Yi Zhou

Hongjun Zhang

David Y Graham

Affiliations

Soon will be listed here.

Abstract

Background & Aims: The decline in Helicobacter pylori cure rates emphasizes the need for readily available methods to determine antimicrobial susceptibility. Our aim was to compare targeted next-generation sequencing (NGS) and culture-based H pylori susceptibility testing using clinical isolates and paired formalin-fixed, paraffin-embedded (FFPE) gastric biopsies.

Methods: H pylori isolates and FFPE tissues were tested for susceptibility to amoxicillin, clarithromycin, metronidazole, levofloxacin, tetracycline, and rifabutin using agar dilution and NGS targeted to 23S rRNA, gyrA, 16S rRNA, pbp1, rpoB and rdxA. Agreement was quantified using κ statistics.

Results: Paired comparisons included 170 isolates and FFPE tissue for amoxicillin, clarithromycin, metronidazole, and rifabutin and 57 isolates and FFPE tissue for levofloxacin and tetracycline. Agreement between agar dilution and NGS from culture isolates was very good for clarithromycin (κ = 0.90012), good for levofloxacin (κ = 0.78161) and fair for metronidazole (κ = 0.55880), and amoxicillin (κ = 0.21400). Only 1 isolate was resistant to tetracycline (culture) and 1 to rifabutin (NGS). Comparison of NGS from tissue blocks and agar dilution from isolates from the same stomachs demonstrated good accuracy to predict resistance for clarithromycin (94.1%), amoxicillin (95.9%), metronidazole (77%), levofloxacin (87.7%), and tetracycline (98.2%). Lack of resistance precluded comparisons for tetracycline and rifabutin.

Conclusions: Compared with agar dilution, NGS reliably determined resistance to clarithromycin, levofloxacin, rifabutin, and tetracycline from clinical isolates and formalin-fixed gastric tissue. Consistency was fair for metronidazole and amoxicillin. Culture-based testing can predict treatment outcomes with clarithromycin and levofloxacin. Studies are needed to compare the relative ability of both methods to predict treatment outcomes for other antibiotics.

Citing Articles

Analysis of antibiotic susceptibility and genomic characteristics of Helicobacter pylori by whole-genome resequencing in Northern China.

Wang Y, Jiang T, Liu X, Sa R, Zhu X, Hu J Braz J Microbiol. 2024; 56(1):487-498.

PMID: 39661273 PMC: 11885719. DOI: 10.1007/s42770-024-01582-w.

Development and validation of next-generation sequencing panel for personalized eradication treatment targeting multiple species.

Min B, Seo M, Bae J, Kim J, Kim J Front Cell Infect Microbiol. 2024; 14:1379790.

PMID: 39268485 PMC: 11390507. DOI: 10.3389/fcimb.2024.1379790.

Antimicrobial Resistance and the Role of Next-Generation Sequencing.

Andrews C, Herzlinger M, Moss S Gastroenterol Hepatol (N Y). 2024; 20(8):469-476.

PMID: 39205950 PMC: 11348536.

Genetic Markers of Resistance to Clarithromycin and Levofloxacin in Moscow, Russia.

Bodunova N, Tsapkova L, Polyakova V, Baratova I, Rumyantsev K, Dekhnich N Curr Issues Mol Biol. 2024; 46(7):6665-6674.

PMID: 39057039 PMC: 11276122. DOI: 10.3390/cimb46070397.

A Prototype of Graphene E-Nose for Exhaled Breath Detection and Label-Free Diagnosis of Helicobacter Pylori Infection.

Liu X, Chen Q, Xu S, Wu J, Zhao J, He Z Adv Sci (Weinh). 2024; 11(34):e2401695.

PMID: 38965802 PMC: 11425842. DOI: 10.1002/advs.202401695.

References

Yu L, Luo L, Long X, Liang X, Ji Y, Chen Q . Susceptibility-guided therapy for infection treatment failures. Therap Adv Gastroenterol. 2019; 12:1756284819874922. PMC: 6734621. DOI: 10.1177/1756284819874922. View

Graham D, El-Serag H . European Registry on management shows that gastroenterology has largely failed in its efforts to guide practitioners. Gut. 2020; 70(1):1-2. PMC: 10506726. DOI: 10.1136/gutjnl-2020-322385. View

Luo L, Huang Y, Liang X, Ji Y, Yu L, Lu H . Susceptibility-guided therapy for Helicobacter pylori-infected penicillin-allergic patients: A prospective clinical trial of first-line and rescue therapies. Helicobacter. 2020; 25(4):e12699. DOI: 10.1111/hel.12699. View

Rimbara E, Noguchi N, Kawai T, Sasatsu M . Mutations in penicillin-binding proteins 1, 2 and 3 are responsible for amoxicillin resistance in Helicobacter pylori. J Antimicrob Chemother. 2008; 61(5):995-8. DOI: 10.1093/jac/dkn051. View

Gerrits M, de Zoete M, Arents N, Kuipers E, Kusters J . 16S rRNA mutation-mediated tetracycline resistance in Helicobacter pylori. Antimicrob Agents Chemother. 2002; 46(9):2996-3000. PMC: 127406. DOI: 10.1128/AAC.46.9.2996-3000.2002. View

Okamoto T, Yoshiyama H, Nakazawa T, Chang M, Yanai H, Okita K . A change in PBP1 is involved in amoxicillin resistance of clinical isolates of Helicobacter pylori. J Antimicrob Chemother. 2002; 50(6):849-56. DOI: 10.1093/jac/dkf140. View

Gerrits M, Berning M, Van Vliet A, Kuipers E, Kusters J . Effects of 16S rRNA gene mutations on tetracycline resistance in Helicobacter pylori. Antimicrob Agents Chemother. 2003; 47(9):2984-6. PMC: 182601. DOI: 10.1128/AAC.47.9.2984-2986.2003. View

Graham D, Canaan Y, Maher J, Wiener G, Hulten K, Kalfus I . Rifabutin-Based Triple Therapy (RHB-105) for Eradication: A Double-Blind, Randomized, Controlled Trial. Ann Intern Med. 2020; 172(12):795-802. DOI: 10.7326/M19-3734. View

Chen M, Wu M, Chen C, Chen C, Fang Y, Bair M . Impact of amoxicillin resistance on the efficacy of amoxicillin-containing regimens for Helicobacter pylori eradication: analysis of five randomized trials. J Antimicrob Chemother. 2017; 72(12):3481-3489. DOI: 10.1093/jac/dkx320. View

10.

Nyssen O, Bordin D, Tepes B, Perez-Aisa A, Vaira D, Caldas M . European Registry on management (Hp-EuReg): patterns and trends in first-line empirical eradication prescription and outcomes of 5 years and 21 533 patients. Gut. 2020; 70(1):40-54. DOI: 10.1136/gutjnl-2020-321372. View

11.

Saracino I, Pavoni M, Zullo A, Fiorini G, Lazzarotto T, Borghi C . Next Generation Sequencing for the Prediction of the Antibiotic Resistance in : A Literature Review. Antibiotics (Basel). 2021; 10(4). PMC: 8070836. DOI: 10.3390/antibiotics10040437. View

12.

Wenzhen Y, Yumin L, Quanlin G, Kehu Y, Lei J, Donghai W . Is antimicrobial susceptibility testing necessary before first-line treatment for Helicobacter pylori infection? Meta-analysis of randomized controlled trials. Intern Med. 2010; 49(12):1103-9. DOI: 10.2169/internalmedicine.49.3031. View

13.

Jindal H, Ramanathan B, Le C, Gudimella R, Razali R, Manikam R . Comparative genomic analysis of ten clinical Streptococcus pneumoniae collected from a Malaysian hospital reveal 31 new unique drug-resistant SNPs using whole genome sequencing. J Biomed Sci. 2018; 25(1):15. PMC: 5815235. DOI: 10.1186/s12929-018-0414-8. View

14.

Lopez-Gongora S, Puig I, Calvet X, Villoria A, Baylina M, Munoz N . Systematic review and meta-analysis: susceptibility-guided versus empirical antibiotic treatment for Helicobacter pylori infection. J Antimicrob Chemother. 2015; 70(9):2447-55. DOI: 10.1093/jac/dkv155. View

15.

Argueta E, Alsamman M, Moss S, DAgata E . Impact of Antimicrobial Resistance Rates on Eradication of Helicobacter pylori in a US Population. Gastroenterology. 2021; 160(6):2181-2183.e1. PMC: 9115583. DOI: 10.1053/j.gastro.2021.02.014. View

16.

Chawla K, Martinez E, Kumar A, Shenoy V, Sintchenko V . Whole-genome sequencing reveals genetic signature of bedaquiline resistance in a clinical isolate of Mycobacterium tuberculosis. J Glob Antimicrob Resist. 2018; 15:103-104. DOI: 10.1016/j.jgar.2018.09.006. View

17.

Dore M, Kwon D, Sepulveda A, Graham D, Realdi G . Stable amoxicillin resistance in Helicobacter pylori. Helicobacter. 2001; 6(1):79. DOI: 10.1046/j.1523-5378.2001.00002.x. View

18.

Attumi T, Graham D . Increasing the duration of dual amoxicillin plus omeprazole Helicobacter pylori eradication to 6 weeks: a pilot study. J Gastroenterol Hepatol. 2011; 27(1):59-61. PMC: 3212627. DOI: 10.1111/j.1440-1746.2011.06876.x. View

19.

Azzaya D, Gantuya B, Oyuntsetseg K, Davaadorj D, Matsumoto T, Akada J . High Antibiotic Resistance of and Its Associated Novel Gene Mutations among the Mongolian Population. Microorganisms. 2020; 8(7). PMC: 7409119. DOI: 10.3390/microorganisms8071062. View

20.

Hu Y, Zhang M, Lu B, Dai J . Helicobacter pylori and Antibiotic Resistance, A Continuing and Intractable Problem. Helicobacter. 2016; 21(5):349-63. DOI: 10.1111/hel.12299. View